FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 石四藥集團有限公司 呈交日期： 2025年11月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02005 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關 ...

Core Viewpoint - The company Shijiazhuang Pharmaceutical Group has received production registration approvals from the National Medical Products Administration of China for several pharmaceutical products, indicating significant progress in its product portfolio and market positioning [1] Group 1: Product Approvals - The company has obtained production registration for Aminophylline Tablets (100mg), classified as a Class 3 chemical drug, making it the third domestic company to receive such approval [1] - Aminophylline Tablets are primarily used for alleviating symptoms of bronchial asthma, asthmatic bronchitis, and obstructive pulmonary emphysema, and can also treat asthma caused by cardiogenic pulmonary edema [1] - The company's raw material for Aminophylline has also been approved for use in marketed formulations by the National Medical Products Administration [1] Group 2: Additional Product Approvals - The company has also secured production registration for Hydrochloride of Picarbital Inhalation Solution (0.5ml: 50μg) and Injection of Dihydrosodium Adenosine Triphosphate (0.5g), classified as Class 3 and Class 4 chemical drugs respectively [1] - Hydrochloride of Picarbital Inhalation Solution is mainly used to relieve symptoms associated with bronchial asthma, chronic bronchitis, and emphysema with airflow limitation [1] - Injection of Dihydrosodium Adenosine Triphosphate is primarily used for treating intrahepatic cholestasis caused by liver cirrhosis and cholestasis during pregnancy [1]

董事局亦欣然公告，本集团已取得国家药监局有关盐酸丙卡特罗吸入溶液(0.5ml：50μg)及注射用丁二 磺酸腺苷蛋氨酸(0.5g)的药品生产注册批件，分别属于化学药品第3类及第4类，视同通过一致性评价。 盐酸丙卡特罗吸入溶液主要用于缓解支气管哮喘、慢性支气管炎及肺气肿以气流受限为基础的各种症 状。注射用丁二磺酸腺苷蛋氨酸主要用于治疗肝硬化前和肝硬化所致的肝内胆汁淤积，以及妊娠期的肝 内胆汁淤积。 智通财经APP讯，石四药集团(02005)发布公告，本集团已取得中国国家药品监督管理局(国家药监局)有 关氨茶硷片(100mg)的药品生产注册批件，属于化学药品第3类，视同通过一致性评价，是国内企业第三 家获批。氨茶硷片主要用于支气管哮喘、喘息型支气管炎、阻塞性肺气肿等缓解喘息症状，也可用于治 疗心源性肺水肿引起的哮喘。本集团的氨茶硷原料药已获国家药监局批准登记成为在上市制剂使用的原 料药。 ...

Core Viewpoint - The company has received production registration approvals from the National Medical Products Administration for several pharmaceutical products, indicating a significant advancement in its product portfolio and market position in the pharmaceutical industry [1] Group 1: Product Approvals - The company has obtained the production registration approval for Aminophylline Tablets (100mg), classified as a Class 3 chemical drug, making it the third domestic company to receive such approval [1] - Aminophylline Tablets are primarily used for alleviating symptoms of bronchial asthma, asthmatic bronchitis, and obstructive pulmonary emphysema, and can also be used to treat asthma caused by cardiogenic pulmonary edema [1] - The company’s Aminophylline raw material has also been approved for use in marketed formulations by the National Medical Products Administration [1] Group 2: Additional Product Approvals - The company has secured production registration approvals for Salbutamol Inhalation Solution (0.5ml: 50μg) and Injection Adenosine Methionine (0.5g), classified as Class 3 and Class 4 chemical drugs, respectively [1] - Salbutamol Inhalation Solution is mainly used to relieve symptoms associated with bronchial asthma, chronic bronchitis, and emphysema based on airflow limitation [1] - Injection Adenosine Methionine is primarily used for treating intrahepatic cholestasis caused by liver cirrhosis and cholestasis during pregnancy [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團已取得中國國家藥品監督管理局（「國家藥監局」）有關氨茶鹼片（100mg）的藥品生產 註冊批件，屬於化學藥品第3類，視同通過一致性評價，是國內企業第三家獲批。氨茶鹼片主要 用於支氣管哮喘、喘息型支氣管炎、阻塞性肺氣腫等緩解喘息症狀，也可用於治療心源性肺水 腫引起的哮喘。本集團的氨茶鹼原料藥已獲國家藥監局批准登記成為在上市製劑使用的原料藥。 董事局亦欣然公告，本集團已取得國家藥監局有關鹽酸丙卡特羅吸入溶液(0.5ml：50μg)及注射 用丁二磺酸腺苷蛋氨酸(0.5g)的藥品生產註冊批件，分別屬於化學藥品第3類及第4類，視同通 過一致性評價。鹽酸丙卡特羅吸入溶液主要用於緩解支氣管哮喘、慢性支氣管炎及肺氣腫以氣 流受限為基礎的各種症狀。注射用丁二磺酸腺苷蛋氨酸主要用於治療肝硬化前和肝 ...

Core Viewpoint - The recent increase in shareholding by Kelun Pharmaceutical in Shijiazhuang Yiling Pharmaceutical reflects a strategic move amidst declining profits for both companies, indicating a survival strategy rather than expansion [1][3]. Group 1: Financial Performance - Kelun Pharmaceutical's net profit for the first three quarters of 2025 plummeted by 51.41% to 1.201 billion yuan, while Shijiazhuang Yiling's net profit dropped by 58.7% to 283.5 million Hong Kong dollars [1][2]. - The total revenue for Kelun in the same period was 13.277 billion yuan, down 20.92% year-on-year [2]. - The decline in net profit for Kelun was significantly influenced by the poor performance of its joint venture with Shijiazhuang Yiling, which saw a 38.39% decrease in investment income [7]. Group 2: Strategic Moves - The increase to a 23.03% stake in Shijiazhuang Yiling allows Kelun to enhance its influence while avoiding the 30% threshold for mandatory takeover bids, showcasing a calculated approach to capital management [3]. - The long-term relationship between Kelun and Shijiazhuang Yiling has evolved from competition to cooperation, with both companies forming a "triangle alliance" to stabilize prices and avoid destructive competition [5][4]. - The collaboration includes joint procurement and sales agreements, which help mitigate the impact of price pressures in the intravenous infusion market [5]. Group 3: Market Challenges - The intravenous infusion market is facing significant challenges, including regulatory pressures and price reductions due to centralized procurement, leading to a 19.65% decline in sales revenue for Kelun's core infusion business [8][9]. - The company's traditional business is under severe pressure, while new business segments have not yet compensated for the losses, creating a transitional struggle [10]. Group 4: Marketing and Public Perception - The controversial marketing campaign led by Chairman Liu Gexin, which involved him promoting a health product, reflects the company's anxiety over declining performance and the need for innovative marketing strategies [11][12]. - Despite the backlash, the campaign generated significant revenue, indicating a potential shift towards the health product market, which is projected to be worth 12.3 trillion yuan [12][15]. - The strategic partnership with the Thailand Miracle Life Foundation aims to enhance pharmaceutical innovation and expand into the health product sector, further indicating Kelun's commitment to diversifying its business model [15].

吲哚布芬片主要用于治疗动脉硬化引起的缺血性心血管病变、缺血性脑血管病变及静脉血栓形成，也可 用于血液透析时预防血栓形成。 （原标题：石四药集团(02005)：取得吲哚布芬片(0.2g)药品生产注册批件） 智通财经APP讯，石四药集团(02005)发布公告，集团已取得中国国家药品监督管理局有关吲哚布芬片 (0.2g)的药品生产注册批件，属于化学药品第3类，视同通过一致性评价。 ...

Core Viewpoint - The company has obtained the drug production registration approval from the National Medical Products Administration of China for Indobufene Tablets (0.2g), classified as a Class 3 chemical drug, which is considered equivalent to passing the consistency evaluation [1] Group 1 - Indobufene Tablets are primarily used for the treatment of ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis [1] - The drug can also be used to prevent thrombosis during hemodialysis [1]

Core Viewpoint - The company has obtained the production registration approval for Indobufene Tablets (0.2g) from the National Medical Products Administration of China, which is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation [1] Group 1: Product Information - Indobufene Tablets are primarily used for the treatment of ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis [1] - The drug can also be used to prevent thrombosis during hemodialysis [1]

Core Viewpoint - The company Shijiazhuang Fourth Pharmaceutical Group has obtained the production registration approval from the National Medical Products Administration of China for Indobufene Tablets (0.2g), classified as a Class 3 chemical drug, which is considered equivalent to passing the consistency evaluation [1] Group 1 - Indobufene Tablets are primarily used for the treatment of ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis, and can also be used to prevent thrombosis during hemodialysis [1]